每周股票复盘：方盛制药（603998）养血祛风止痛颗粒纳入2025医保

Core Viewpoint - Fangsheng Pharmaceutical (603998) is focusing on the development of innovative traditional Chinese medicine (TCM) products, with plans to enhance its product pipeline and achieve significant sales growth in the coming years [1] Company Announcements - The company held a product launch event for its new product, Yao Xue Qu Feng Zhi Tong Granules, on December 21, 2025, discussing its operational status, R&D progress, and market strategy [1] - Yao Xue Qu Feng Zhi Tong Granules has been included in the 2025 National Medical Insurance Directory, with plans to cover over 500 medical institutions by 2026 [2] - Fangsheng Pharmaceutical has successfully launched two innovative TCM products and aims to create a product matrix with annual sales of 300-500 million yuan [2] - The industrial hemp subsidiary has achieved large-scale production and overseas sales [2]